Evidence map›Paper›PMID 37419957›Full record

ArticleEye (London, England)2024

The Infectious Uveitis Treatment Algorithm Network (TITAN) Report 1-global current practice patterns for the management of Herpes Simplex Virus and Varicella Zoster Virus anterior uveitis.

Zheng Xian Thng, Ikhwanuliman Putera, Ilaria Testi, Kevin Chan, Mark Westcott, Soon-Phaik Chee, Andrew D Dick, John H Kempen, Bahram Bodaghi, Jennifer E Thorne and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Zheng Xian Thng *National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore.ORCID 0000-0003-3275-7537
Ikhwanuliman Putera *Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Kirana Eye Hospital, Jakarta, Indonesia.ORCID 0000-0002-9350-5133
Ilaria TestiNational Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Kevin ChanLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Mark WestcottNational Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Soon-Phaik CheeSingapore National Eye Centre, Singapore, Singapore.
Andrew D DickNational Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
John H KempenDepartment of Ophthalmology, Massachusetts Eye and Ear/Harvard Medical School, and Schepens Eye Research Institute, Boston, MA, USA.ORCID 0000-0002-2967-4792
Bahram BodaghiDepartment of Ophthalmology, IHU FOReSIGHT, Sorbonne-APHP, 47-83 bd de l'Hopital, 75013, Paris, France.
Jennifer E ThorneWilmer Eye Institute, Department of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Talin Barisani-AsenbauerInstitute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Marc D de SmetDepartment of Ophthalmology, Leiden University, Leiden, The Netherlands.
Justine R SmithFlinders University College of Medicine and Public Health, Adelaide, SA, Australia.
Peter McCluskeyDepartment of Ophthalmology, Save Sight Institute, The University of Sydney, Sydney, NSW, Australia.
Rina La Distia NoraDepartment of Ophthalmology, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Kirana Eye Hospital, Jakarta, Indonesia.
Douglas A JabsWilmer Eye Institute, Department of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Joke H de BoerDepartment of Ophthalmology, Utrecht University Medical Center, Utrecht, The Netherlands.
H Nida SenNational Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Debra A GoldsteinFeinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Moncef KhairallahDepartment of Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia.
Janet L DavisBascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0001-6395-5881
James T RosenbaumOregon Health and Science University, Portland, OR, USA.
Nicholas P JonesSchool of Biological Sciences, University of Manchester, Manchester, UK.
Quan Dong NguyenByers Eye Institute, Stanford Medical School, Stanford, CA, USA.
Carlos PavesioNational Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Rupesh AgrawalNational Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore. rupesh_agrawal@ttsh.com.sg.ORCID 0000-0002-6662-5850
Vishali GuptaAdvanced Eye Centre, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. vishalisara@yahoo.co.in.
TITAN consensus guidelines group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo present current expert practice patterns and to formulate a consensus for the management of HSV and VZV AU by uveitis specialists worldwide.

methodsA two-round online modified Delphi survey with masking of the study team was conducted. Responses were collected from 76 international uveitis experts from 21 countries. Current practices in the diagnosis and treatment of HSV and VZV AU were identified. A working group (The Infectious Uveitis Treatment Algorithm Network [TITAN]) developed data into consensus guidelines. Consensus is defined as a particular response towards a specific question meeting ≥75% of agreement or IQR ≤ 1 when a Likert scale is used.

resultsUnilaterality, increased intraocular pressure (IOP), decreased corneal sensation and diffuse or sectoral iris atrophy are quite specific for HSV or VZV AU from consensus opinion. Sectoral iris atrophy is characteristic of HSV AU. Treatment initiation is highly variable, but most experts preferred valacyclovir owing to simpler dosing. Topical corticosteroids and beta-blockers should be used if necessary. Resolution of inflammation and normalisation of IOP are clinical endpoints.

conclusionsConsensus was reached on several aspects of diagnosis, choice of initial treatment, and treatment endpoints for HSV and VZV AU. Treatment duration and management of recurrences varied between experts.

Indexed as

Herpes SimplexHerpes ZosterHerpes Zoster OphthalmicusUveitisUveitis, AnteriorAtrophyHerpesvirus 3, HumanHumansSimplexvirus

Identifiers

PMID37419957
PMCPMC10764303

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.